BioSpace News Archive

PAVmed Inc. today announced that Lishan Aklog, M.D. , PAVmed’s Chairman and CEO, will participate in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries virtual panel discussion on November 21, 2022 from 12:00 pm to 12:55 pm EST.

Immunocore Holdings plc (Nasdaq: IMCR) has today presented new translational data on KIMMTRAK (tebentafusp-tebn) in patients with metastatic uveal melanoma at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.

Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, presented preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, today at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

ImCheck Therapeutics presented today the first patient data from EVICTION-2, a Phase I/II clinical trial evaluating the combination of ImCheck’s lead program, ICT01, a γ9δ2 T cell-activating monoclonal antibody targeting BTN3A, combined with low-dose (LD) IL-2, to selectively expand the number of γ9δ2 T cells in relapsed/refractory patients with solid tumors.

Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, is expanding its portfolio.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has concluded the merger transaction with Emerald Health Therapeutics (“Emerald”). Both companies’ shareholders voted in favor of the transaction and the Supreme Court of British Columbia approved the transaction.

The Nutraceuticals Market was valued at US$ 498.86 billion in 2021 and is anticipated to reach US$ 1025 billion by 2030, growing at an estimated CAGR of 8.33% from 2022 to 2030.

As per Precedence Research, the global biopharmaceutical CMO and CRO market size is predicted to surpass US$ 59.13 billion by 2030 and growing at a CAGR of 7.4% from 2022 to 2030.

According to Latest Report Study, the global biosimilars market size is expected to worth around USD 66.2 billion by 2030 and growing at a registered CAGR 17.5% over the forecast period 2021 to 2030.